A possible clinical application of multicytokine-producing cytotoxic mononuclear cell (MCCM) therapy |
| |
| Authors: | Mitsuo Katano Eiro Kubota Hiroshi Yamamoto Mitsunari Nakamura Tatsuya Matsuo Takeharau Hisatsugu Takeshi Katsuki Hisao Koga Kiyonobu Ikezaki Kazuo Tabuchi Fumio Nagumo Jutaro Tadano |
| |
| Affiliation: | (1) Department of Surgery, Saga Medical School, 5-1-1 Nabeshima, 849 Saga, Japan;(2) Department of Oral and Maxillofacial Surgery, Saga Medical School, 5-1-1 Nabeshima, 849 Saga, Japan;(3) Department of Neurosurgery, Saga Medical School, 5-1-1 Nabeshima, 849 Saga, Japan;(4) Hospital Laboratory, Saga Medical School, 5-1-1 Nabeshima, 849 Saga, Japan |
| |
| Abstract: | When peripheral blood mononuclear cells (PBMC) were incubated with a streptococcal preparation, OK-432, for 24 h, PBMC acquired cytolytic activity against cultured and fresh human tumor cells. Such PBMC were called OK-432-activated mononuclear cells (OK-MC). OK-MC produce several kinds of cytokines such as interferon (IFN), IFN , and tumor growth inhibitory factor (TGIF) bothin vitro andin vivo. OK-MC-produced cytokines also inhibited the growth of cultured and fresh human tumor cells. The growth inhibition was examined by human tumor clonogenic assay using a double-layer agar technique. The results indicate that two pathways of anti-tumor activity are induced in OK-MC, i.e., cell-mediated and cytokine-mediated. |
| |
| Keywords: | IFNs multicytokine-producing mononuclear cells OK-432 TGIF |
| 本文献已被 SpringerLink 等数据库收录！ |
|
